Deletion of CDKN2A/B is associated with inferior relapse free survival in pediatric B cell acute lymphoblastic leukemia. Issue 2 (28th January 2019)

• Record Type: Journal Article
• Authors: Kathiravan, M.; Singh, Minu; Bhatia, Prateek; Trehan, Amita; Varma, Neelam; Sachdeva, Manupdesh Singh; Bansal, Deepak; Jain, Richa; Naseem, Shano
• Is Part Of: Leukemia & lymphoma. Volume 60:Issue 2(2019)
• Page Start: 433
• Page End: 441
• Publication Date: 2019-01-28
• Subjects: Acute lymphoblastic leukemia -- BCP-ALL -- MLPA -- copy number abnormality -- CDKN2A/B -- minimal residual disease; Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.1080/10428194.2018.1482542
• Languages: English
• ISSNs: 1042-8194

Abstract

Abstract: Considering conflicting data on CDKN2A/B deletion in ALL, this study to assess its prognostic significance as an independent marker in a total of 96 pediatric B and T-ALL cases was planned. The overall frequency of CDKN2A/B deletion was 44% ( n = 43) with 36% (30/83) in B-ALL and 100% (13/13) in T-ALL. CDKN2A/B deletion was significantly associated with high WBC count ( p = .002) and National Cancer Institute risk ( p = .01) in B-ALL. Importantly, CDKN2A/B deletion cases had poor EFS of 42% at 28 months compared to EFS of 90% in rest ( p = .0004). Further, relapse free survival was only 56% for cases with CDKN2A/B deletions ( n = 25), compared to 100% in control group ( p = .001). Moreover, CDKN2A/B deletion was the only risk factor associated with early relapse ( p = .01) compared to IKZF1 deletion ( p = .73) or occurrence of BCR-ABL1 fusion transcript ( p = .26). Thus our study data highlights potential prognostic role of CDKN2A/B deletions in early disease stratification in pediatric B-ALL.